Caplacizumab for pediatric immune thrombotic thrombocytopenic Purpura: A scoping review of current evidence

Caplacizumab for pediatric immune thrombotic thrombocytopenic Purpura: A scoping review of current evidence

<p>While caplacizumab, a von Willebrand factor inhibitor, has dramatically improved iTTP management in adults, its role in pediatric iTTP remains understudied. This scoping review synthesizes current evidence on the safety and efficacy of caplacizumab in children with iTTP. We conducted a syst...

Full description

Saved in:
Bibliographic Details
Main Author: Abdulrahman F. Al-Mashdali (17148316) (author)
Other Authors: Samah M. Salih (21837866) (author), Priyadarshini Asmita Vatsyayan (21837869) (author), Deena Mudawi (16441978) (author), Sarah A. Elkourashy (21632903) (author), Honar Cherif (17746722) (author), Shehab F. Mohamed (17945561) (author)
Published: 2025
Subjects:
Biomedical and clinical sciences
Immunology
Paediatrics
Pharmacology and pharmaceutical sciences
Caplacizumab
Pediatric
Children
Thrombotic thrombocytopenic purpurai
TTP
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items